Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MTEM NASDAQ:RYTM NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/ARYTMRhythm Pharmaceuticals$94.17-2.1%$87.93$55.31▼$122.20$6.59B1.94693,472 shs882,554 shsSTOKStoke Therapeutics$32.89+0.3%$34.34$8.70▼$40.22$2.04B1.2488,114 shs693,127 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTEMMolecular Templates0.00%0.00%0.00%0.00%0.00%RYTMRhythm Pharmaceuticals0.00%+18.28%+12.58%-7.12%+49.32%STOKStoke Therapeutics0.00%+0.21%-5.97%+1.20%+278.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMTEMMolecular Templates$0.00$0.00▼$1.59$1K1.535.62 million shsN/ARYTMRhythm Pharmaceuticals$94.17-2.1%$87.93$55.31▼$122.20$6.59B1.94693,472 shs882,554 shsSTOKStoke Therapeutics$32.89+0.3%$34.34$8.70▼$40.22$2.04B1.2488,114 shs693,127 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMTEMMolecular Templates0.00%0.00%0.00%0.00%0.00%RYTMRhythm Pharmaceuticals0.00%+18.28%+12.58%-7.12%+49.32%STOKStoke Therapeutics0.00%+0.21%-5.97%+1.20%+278.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMTEMMolecular Templates 0.00N/AN/AN/ARYTMRhythm Pharmaceuticals 2.84Moderate Buy$131.8139.97% UpsideSTOKStoke Therapeutics 2.92Moderate Buy$41.8327.19% UpsideCurrent Analyst Ratings BreakdownLatest STOK, RYTM, and MTEM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026RYTMRhythm Pharmaceuticals Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$140.00 ➝ $143.005/6/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$136.00 ➝ $137.005/6/2026RYTMRhythm Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$143.00 ➝ $144.004/21/2026RYTMRhythm Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/20/2026STOKStoke Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$36.00 ➝ $60.003/19/2026STOKStoke Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.003/18/2026RYTMRhythm Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$110.00 ➝ $100.003/18/2026STOKStoke Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.003/17/2026RYTMRhythm Pharmaceuticals CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $131.003/17/2026RYTMRhythm Pharmaceuticals Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$140.00 ➝ $130.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMTEMMolecular Templates$23.48M0.00N/AN/A$0.78 per share0.00RYTMRhythm Pharmaceuticals$189.76M34.01N/AN/A$1.79 per share52.61STOKStoke Therapeutics$184.42M11.11N/AN/A$6.17 per share5.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMTEMMolecular Templates-$8.12M-$2.70N/AN/AN/A-61.35%-260.50%-46.90%N/ARYTMRhythm Pharmaceuticals-$196.54M-$3.13N/AN/AN/A-93.33%-203.25%-44.99%N/ASTOKStoke Therapeutics-$6.89M-$0.12N/AN/AN/A-529.20%-51.16%-43.78%N/ALatest STOK, RYTM, and MTEM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 million5/5/2026Q1 2026RYTMRhythm Pharmaceuticals-$0.86-$0.83+$0.03-$0.83$55.78 million$60.11 million3/16/2026Q4 2025STOKStoke TherapeuticsN/A-$0.97N/A-$0.97N/A$1.40 million2/26/2026Q4 2025RYTMRhythm Pharmaceuticals-$0.79-$0.73+$0.06-$0.73$56.16 million$57.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMTEMMolecular TemplatesN/AN/AN/AN/AN/ARYTMRhythm PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMTEMMolecular TemplatesN/A1.561.56RYTMRhythm PharmaceuticalsN/A4.174.16STOKStoke TherapeuticsN/A5.285.28Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMTEMMolecular Templates95.47%RYTMRhythm PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipMTEMMolecular Templates13.90%RYTMRhythm Pharmaceuticals6.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMTEMMolecular Templates2606.58 million5.67 millionNo DataRYTMRhythm Pharmaceuticals14068.53 million64.35 millionOptionableSTOKStoke Therapeutics10062.27 million56.36 millionOptionableSTOK, RYTM, and MTEM HeadlinesRecent News About These CompaniesStoke Therapeutics Q1 Earnings Call HighlightsMay 8 at 12:06 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Announces Earnings Results, Beats Estimates By $0.01 EPSMay 8 at 6:32 PM | marketbeat.comStoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balanceMay 8 at 7:13 AM | seekingalpha.comStoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business UpdatesMay 8 at 7:13 AM | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call TranscriptMay 8 at 3:02 AM | seekingalpha.comStoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue EstimatesMay 7 at 8:12 PM | zacks.comPrivium Fund Management B.V. Takes Position in Stoke Therapeutics, Inc. $STOKMay 6 at 6:47 AM | marketbeat.comHussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOKMay 3, 2026 | marketbeat.comStoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on ThursdayMay 3, 2026 | marketbeat.comStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesMay 2, 2026 | finance.yahoo.comStoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet SyndromeMay 1, 2026 | seekingalpha.comStoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 26, 2026 | marketbeat.comBaillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOKApril 14, 2026 | marketbeat.comStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | businesswire.comStoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of DirectorsApril 7, 2026 | finance.yahoo.comStoke Therapeutics Auditor Switch Puts Biotech Governance In FocusApril 6, 2026 | finance.yahoo.comStoke Therapeutics (STOK) price target increased by 12.11% to 43.96March 27, 2026 | msn.comStoke Therapeutics Stock Up 340% as Chair Sells $174K in SharesMarch 27, 2026 | fool.comStoke Therapeutics CMO Sells $457,000 in Stock Amid 300% RallyMarch 24, 2026 | fool.comStoke earnings loom as analysts bet big on Dravet therapy potentialMarch 22, 2026 | investing.comStoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 1,461 SharesMarch 20, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTOK, RYTM, and MTEM Company DescriptionsMolecular Templates NASDAQ:MTEMMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Rhythm Pharmaceuticals NASDAQ:RYTM$94.17 -2.06 (-2.14%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$94.16 -0.01 (-0.01%) As of 05/8/2026 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Stoke Therapeutics NASDAQ:STOK$32.89 +0.10 (+0.30%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$31.72 -1.17 (-3.55%) As of 05/8/2026 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
